Agios Awaits FDA Decision on Mitapivat sNDA for Thalassemia—Key Milestone Remains Pending
Market Chameleon (Mon, 8-Dec 7:35 AM)
Agios Reports Strong Hemoglobin Improvements in Sickle Cell Disease Phase 3 Trial—Mitapivat Delivers Clear Benefit in Key Patient Subset
Market Chameleon (Thu, 20-Nov 10:35 AM)
Mitapivat Shows Strong Hemoglobin Improvement in Agios’s RISE UP Sickle Cell Trial—Key Benefits Seen in Responder Subgroup
Market Chameleon (Wed, 19-Nov 7:33 AM)
